REG - PureTech Health PLC - Total Voting Rights

Puretech HealthAnnouncement

01/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240501:nRSA7056Ma&default-theme=true

RNS Number : 7056M  PureTech Health PLC  01 May 2024

PureTech Health plc

 

Total Voting Rights and Share Capital - Month End Disclosure

 

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

 

As at 30 April 2024 the issued share capital of PureTech Health plc comprised
289,468,159 Ordinary Shares of one pence each. There were 19,055,414 shares
held in treasury.

 

The total number of voting rights in PureTech Health plc is therefore
270,412,745.

 

This information may be used by shareholders in their calculations to
determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X
(formerly Twitter) @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements.
The forward-looking statements are based on current expectations and are
subject to known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under the caption
"Risk Factors" in our Annual Report on Form 20-F for the year ended December
31, 2023 filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

 Contact:

 Investor Relations

 IR@puretechhealth.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRWPUWACUPCGBU